Idex Corporation Lifts 2026 Outlook After Strong Q1

Idex Corporation ((IEX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Idex Corporation’s latest earnings call struck an upbeat tone as management delivered better-than-expected Q1 results and raised full-year guidance. Executives acknowledged pockets of softness in certain industrial and life sciences markets, but emphasized strong order momentum, expanding margins and ample balance-sheet flexibility as reasons for increased confidence in the multi-year outlook.

Upgraded Growth Outlook for 2026

Idex lifted its full-year 2026 organic growth target to 3%–4%, up from 1%–2% previously, citing stronger demand visibility and a healthier backlog. Management highlighted that the revision reflects particular strength in Health & Science Technologies, which is expected to offset flattish trends in the company’s other two segments.

Q1 Orders and Revenue Beat Expectations

The company posted 5% organic sales growth in the first quarter, while consolidated organic orders climbed about 10% year over year, coming in ahead of internal expectations. The strong order intake suggests solid near-term demand, giving Idex a firmer foundation for the rest of 2026 despite uneven conditions in some short-cycle markets.

Health & Science Technologies Drives Outperformance

Health & Science Technologies stood out with organic orders up 17% and organic revenue up 11% in Q1, along with roughly 100 basis points of adjusted EBITDA margin expansion. Management pointed to durable secular tailwinds in data centers, semiconductors, space and defense, and pharma as the key demand engines supporting this sustained outperformance.

Consolidated Margin Expansion Continues

At the corporate level, Idex delivered a 26% adjusted EBITDA margin in Q1, a 50 basis-point improvement from a year ago. Executives credited productivity gains, volume leverage and disciplined price/cost management, underscoring the company’s ability to expand profitability even amid some mix-related headwinds.

Backlog Builds Visibility Into 2027

Management reported a notable backlog build, particularly within HST, which is providing better line-of-sight into the back half of 2026 and into 2027. This enhanced visibility underpins their conviction in a multi-year growth runway, reducing dependence on volatile short-cycle industrial demand.

Balanced Capital Returns and Strong Liquidity

Idex returned cash aggressively in Q1, repurchasing $76 million of stock and paying $53 million in dividends, and plans to maintain a similar buyback pace throughout 2026. The company exited the quarter with roughly $1.1 billion in available liquidity and gross leverage near 2x, leaving ample capacity for both shareholder returns and strategic investments.

EPS Outlook Raised on Solid Execution

Reflecting its stronger operating performance and improved demand picture, Idex raised its 2026 adjusted EPS range by $0.20 to $8.35–$8.55, implying mid- to high-single-digit growth versus last year. For Q2, management guided to adjusted EPS of $2.07–$2.12, in line with the upgraded full-year trajectory.

Active Pipeline for Bolt-On M&A

The company reiterated that it is actively pursuing bolt-on acquisitions to supplement organic growth while continuing its current share repurchase cadence. Recent acquired businesses are already contributing to top-line momentum, with management focused on integrating them and lifting their margins toward segment averages over time.

FSDP and Short-Cycle Industrials Show Soft Spots

Not all segments participated equally in the upswing, as Fluid & Metering Technologies’ sister platform, FSDP, saw organic orders decline 4% and organic sales slip 1% in Q1. Weakness in the dispensing business, due to tough comparisons and lower project volumes in North America and Asia, offset high single-digit growth in Fire & Safety, while short-cycle industrial markets remained choppy.

FMT Growth Positive but Mixed

In Fluid & Metering Technologies, orders grew 9% but organic sales rose only 2%, reflecting a lag between bookings and shipments. The segment’s adjusted EBITDA margin dipped about 10 basis points year over year because of unfavorable mix and volume deleverage, as softness in chemical markets partially offset solid performance in water and pump applications.

Life Sciences Weighed Down by China and Funding

Within HST, life sciences businesses faced pressure from weak demand in China and constrained academic and research funding, which held growth to low single digits in that subsegment. The slower, lower-margin life sciences mix also damped the broader segment’s margin upside, even as other HST end markets performed strongly.

Gross Margin Pressured by Unfavorable Mix

Despite EBITDA margin expansion, adjusted gross margin edged down about 40 basis points to 44.9% in Q1 as productivity and higher volumes were more than offset by mix. Management noted that the blend of businesses and end markets, including contributions from acquisitions with lower starting margins, temporarily weighed on gross profitability.

Seasonal Dip in Free Cash Flow

Free cash flow came in at $86 million for the quarter, down $5 million from the prior year, mainly due to higher working capital needs associated with stronger growth. Executives framed Q1 as seasonally the weakest cash quarter and reiterated their expectation to convert at least 100% of net income to free cash flow over the full year.

Improving Incremental Margins in HST Over Time

HST’s incremental margins have recently run in the low-to-mid 30% range at about 33%, with a target to reach the mid-30s this year and approach 40% over time. Management attributed the current drag to lower-margin acquired businesses and an unfavorable mix, and outlined ongoing 80/20 productivity and portfolio actions aimed at structurally lifting profitability.

Guidance Highlights a Constructive Multi-Year Outlook

Looking ahead, Idex now expects 3%–4% organic growth in 2026, driven by high-single-digit expansion in HST while FMT and FSDP remain roughly flat. The company kept its adjusted EBITDA margin guidance at 26.5%–27.0% and raised adjusted EPS to $8.35–$8.55, with Q2 slated for 3%–4% organic growth, similar margins and EPS between $2.07 and $2.12.

Idex’s earnings call painted a picture of a company leveraging portfolio strengths and disciplined capital allocation to navigate an uneven macro backdrop. Strong HST momentum, expanding margins and upgraded guidance overshadowed modest cash and segment headwinds, leaving investors with a generally positive message on earnings power and long-term growth prospects.